4D Molecular Therapeutics (FDMT) Competitors $4.48 +0.12 (+2.75%) As of 02:14 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. LENZ, OCS, ZYME, NTLA, NUVB, AVBP, IMNM, PHAR, CMRX, and CDMOShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include LENZ Therapeutics (LENZ), Oculis (OCS), Zymeworks (ZYME), Intellia Therapeutics (NTLA), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Immunome (IMNM), Pharming Group (PHAR), Chimerix (CMRX), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Its Competitors LENZ Therapeutics Oculis Zymeworks Intellia Therapeutics Nuvation Bio ArriVent BioPharma Immunome Pharming Group Chimerix Avid Bioservices LENZ Therapeutics (NASDAQ:LENZ) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking. Is LENZ or FDMT more profitable? 4D Molecular Therapeutics' return on equity of -28.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -58.48% -55.50% 4D Molecular Therapeutics N/A -28.00%-26.16% Do analysts recommend LENZ or FDMT? LENZ Therapeutics presently has a consensus price target of $46.60, indicating a potential upside of 57.11%. 4D Molecular Therapeutics has a consensus price target of $29.56, indicating a potential upside of 559.72%. Given 4D Molecular Therapeutics' higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.174D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has higher valuation and earnings, LENZ or FDMT? 4D Molecular Therapeutics has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$124.65M-$1.77-16.764D Molecular Therapeutics$23K9,023.30-$100.84M-$3.18-1.41 Does the MarketBeat Community believe in LENZ or FDMT? 4D Molecular Therapeutics received 44 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 64.13% of users gave 4D Molecular Therapeutics an outperform vote. CompanyUnderperformOutperformLENZ TherapeuticsOutperform Votes15100.00% Underperform VotesNo Votes4D Molecular TherapeuticsOutperform Votes5964.13% Underperform Votes3335.87% Do insiders & institutionals believe in LENZ or FDMT? 54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 6.9% of LENZ Therapeutics shares are owned by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, LENZ or FDMT? LENZ Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Does the media favor LENZ or FDMT? In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 5 mentions for LENZ Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.54 beat LENZ Therapeutics' score of 1.10 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Summary4D Molecular Therapeutics beats LENZ Therapeutics on 13 of the 17 factors compared between the two stocks. Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$207.54M$3.11B$5.60B$8.63BDividend YieldN/A1.57%5.28%4.18%P/E Ratio-1.5733.0627.2520.01Price / Sales9,023.30469.00412.71157.94Price / CashN/A168.6838.2534.64Price / Book0.623.437.124.70Net Income-$100.84M-$72.35M$3.24B$248.05M7 Day Performance14.58%7.86%2.75%2.62%1 Month Performance34.94%18.41%9.00%6.32%1 Year Performance-81.39%-16.84%31.41%13.78% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.977 of 5 stars$4.48+2.8%$29.56+559.7%-81.3%$207.54M$23K-1.57120Analyst ForecastAnalyst RevisionLENZLENZ Therapeutics1.6791 of 5 stars$31.22-2.3%$46.60+49.3%+58.1%$878.72MN/A-17.64110Positive NewsHigh Trading VolumeOCSOculis1.7807 of 5 stars$19.92flat$31.50+58.1%+64.7%$869.75M$980K-10.322Short Interest ↑Analyst RevisionZYMEZymeworks1.8984 of 5 stars$12.45-1.2%$21.00+68.7%+34.0%$866.23M$93.38M-8.30460Positive NewsNTLAIntellia Therapeutics4.5856 of 5 stars$8.28+2.3%$34.95+322.1%-64.8%$857.67M$45.57M-1.52600Analyst RevisionGap DownHigh Trading VolumeNUVBNuvation Bio2.9882 of 5 stars$2.51+1.2%$7.83+212.1%-22.5%$854.06M$10.96M-1.1660Trending NewsAnalyst ForecastHigh Trading VolumeAVBPArriVent BioPharma1.4458 of 5 stars$23.60+0.3%$39.29+66.5%+24.4%$807.43MN/A-6.2640Positive NewsIMNMImmunome1.7865 of 5 stars$9.27+1.5%$23.33+151.7%-39.6%$806.60M$10.94M-1.1440PHARPharming Group2.0584 of 5 stars$11.81-0.4%$30.00+154.0%+32.9%$803.45M$320.71M-45.42280News CoverageShort Interest ↑CMRXChimerix0.6755 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.8423 of 5 stars$12.50+0.1%$12.25-2.0%+56.4%$799.18M$139.91M-5.23320High Trading Volume Related Companies and Tools Related Companies LENZ Alternatives OCS Alternatives ZYME Alternatives NTLA Alternatives NUVB Alternatives AVBP Alternatives IMNM Alternatives PHAR Alternatives CMRX Alternatives CDMO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FDMT Stock Free FDMT Stock Alerts